⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7414350 | 0.94 | — | — | |
| SCHEMBL82321 | 0.94 | — | — | |
| Ammonia Solution, Strong SCHEMBL27662755 | 0.89 | — | — | |
| Hydrogen Sulfide SCHEMBL28022286 | 0.89 | — | — | |
| Water SCHEMBL27996335 | 0.89 | TSHR (0.31) | — | |
| SCHEMBL28376013 | 0.89 | — | — | |
| SCHEMBL30093000 | 0.89 | — | — | |
| SCHEMBL28348968 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL27717534 | 0.89 | — | — | |
| Dimethylamine SCHEMBL6419423 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210794-A1 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | LANTERN PHARMA INC. (US) | 2023-07-06 | — | — | US | claimed |
| US-20180369173-A9 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2018-12-27 | — | — | US | claimed |
| US-20160287539-A1 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | claimed |
| EP-1991237-B1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2252246-B1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8143236-B2 | For reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, chemotherapy-associated toxicities; nucleosides | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8026227-B2 | For reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, chemotherapy-associated toxicities; nucleosides | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| EP-2252246-A1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009113984-A1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| EP-1991237-A2 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080193498-A1 | Chemoprotective methods and compositions | BIONUMERIK PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-6040294-A | THE COMPOUNDS HAVE EITHER A SULFHYDRYL MOIETY OR ARE REDUCIBLE DISULFIDES; REDUCING THE SIDE EFFECT OF CANCER DRUG | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6040304-A | THE COMPOUNDS HAVE EITHER A SULFHYDRYL MOIETY OR ARE REDUCIBLE DISULFIDES; REDUCING THE SIDE EFFECT OF CANCER DRUG, ANTIBIOTICS OR VIRICIDES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6025488-A | MIXTURE OF CRYPTOPHYCIN AND CYTOPROTECTIVE SULFUR COMPOUND; DRUG DELIVERY, SIDE EFFECT REDUCTION | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5919816-A | ADMINISTERING DRUG WITH PROTECTIVE AGENT | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| US-5902610-A | ADMINISTERING WITH OR WITHOUT CISPLATIN IN THE SAME FORMULATION, TO REDUCE TOXIC SIDE EFFECTS OF CISPLATIN IN CANCER THERAPY AND POTENTIATE ITS ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-05-11 | — | — | US | disclosed |
| US-5866617-A | AQUEOUS SOLUTION FOR ADMINISTRATION TO PATIENTS ALSO RECEIVING CISPLATIN; REDUCED SIDE EFFECTS, INCREASED ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5866169-A | LYOPHILIZED FORMULATION WITH CISPLATIN; REDUCED SIDE EFFECTS, INCREASED ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5866615-A | LYOPHILIZED FORMULATION WITH ANTICANCER AGENTS; REDUCED SIDE EFFECTS, INCREASED ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5789000-A | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1998-08-04 | — | — | US | disclosed |